This is the first study to show that kinase activity profiles of tumor tissue exposed ex vivo to a kinase inhibitor may be used to identify (early stage) NSCLC patients who are likely to respond to TKI treatment. A validation study is needed to prove that this profiling method is able to predict response to TKI, also for patients who would otherwise not be eligible for TKItreatment.
Subcategories of NSCLC patients may benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI's), notably those with cancers that harbor mutated EGFR. However, certain patients lacking such mutations might also benefit from TKI treatment. At present, there are no reliable diagnostic tests to identify this patient subset. We used fresh frozen tumor tissue for ex vivo testing of the response to the TKI erlotinib in order to predict the response.
Predict the response to erlotinib in NSCLC patients with phosphorylation-based peptidebiomarkers.
Kinase activity profiles of the 14 lysates were generated in the presence and absence of erlotinib on PamChip® arrays. In the absence of erlotinib, no differential kinase activity profile could be detected between responders and non-responders. Multivariate unsupervised analysis with leave-one-out cross validation resulted in misclassification of 1 sample (responder). The classification in those patients with EGFR or KRAS mutations was coherent with mutation data (among 6 responders 1 showed EGFR ex19 mutation and among 8 non-responders 1 had EGFR ex 20 (9BP inframe deletion) and 3 KRAS codon 12 mutations). These results suggest -kinase inhibitions profiles are able to predict response to erlotinib -based on results of this test, more patients are eligible for erlotinb treatment -since the test assesses the effect of a TKI directly at its target, response prediction may be more reliable than determination of mutation status.
Aim
Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC). Erlotinib treatment Table 1 . Summary of patient groups included in the present study.
Responders

Non-responders
For this study, fresh frozen tumor tissue was used from 14 NSCLC patients (stage IA-IIIA) included in the M06NEL study. This is an open label, multicenter, non-comparative phase II study. Operable patients, 18 years and over, with resectable NSCLC (cT1-3, N0-1) were eligible for the study. The primary lesion had to be measurable (longest diameter ≥ 1 cm measured by spiral CT scan). Preoperative treatment comprised of one tablet of 150 mg erlotinib daily for a period of 3 weeks. Surgical resection involved a radical resection of the tumor, preferably by lobectomy, and regional lymph nodes (at least 3 hilar and three mediastinal lymph node stations). Response evaluation to neo-adjuvant treatment was done by histological assessment of the surgical specimens according to Junker et al (3) . Responders showed > 50% necrosis with signs of therapy related regression. Non-responders had marginal or no regression. All specimens were analyzed for EGFR and KRAS mutation status. 
